Comprehensive review of how therapeutic peptides can enhance cancer immunotherapy by targeting each step of the cancer-immunity cycle, from antigen presentation to checkpoint signaling.
Full CIC coverageTherapeutic peptides can target every step of the cancer-immunity cycle: antigen presentation, immune regulation, and checkpoint signaling
What the researchers found
Therapeutic peptides can enhance cancer immunotherapy by targeting multiple steps of the cancer-immunity cycle, though stability and conformation challenges limit their current clinical efficacy.
Why it matters
Many cancer patients do not respond to current immunotherapies. Peptides that can boost multiple steps of anti-cancer immunity could help more patients benefit from immunotherapy while potentially reducing side effects compared to full-size antibody drugs.
The numbers in context
Review covers peptide applications across all stages of the cancer-immunity cycle, from antigen presentation to tumor killing.
How the study worked
Comprehensive narrative review of recent advancements in therapeutic peptides targeting the cancer-immunity cycle, including clinical progress and emerging strategies.
Who was studied
Review of peptide-based cancer immunotherapy enhancement strategies
What this study cannot tell us
Narrative review that may not comprehensively cover all published evidence. Many discussed peptides are in early clinical stages. Stability and delivery challenges acknowledged but not fully resolved.
How to read the evidence
Moderate evidence: comprehensive review of a rapidly evolving field, though individual peptide approaches are at varying stages of clinical validation.
When this study was published
Published in 2024. Captures the latest advances in peptide-based cancer immunotherapy.
The bigger picture
As cancer immunotherapy becomes standard of care, the need for more precise tools to boost immune responses grows. Peptides occupy a sweet spot between small molecules and antibodies — large enough for specificity but small enough for tissue penetration. This review maps the landscape of how peptides can be deployed across the entire cancer-immunity cycle.
Questions still open
- Which step of the cancer-immunity cycle is most amenable to peptide-based intervention?
- Can peptide stability issues be solved through stapling, cyclization, or formulation approaches?
- Will peptide-based immunotherapies complement or compete with antibody checkpoint inhibitors?
Common questions
How can peptides help fight cancer?
Are peptide cancer therapies available now?
Read the original research
Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.
Acta pharmaceutica Sinica. B, 14(9), 3818-3833
Citation
Zhang, Xiaokun; Wu, Ye; Lin, Jiayi; Lu, Shengxin; Lu, Xinchen; Cheng, Aoyu; Chen, Hongzhuan; Zhang, Weidong; Luan, Xin. (2024). Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.. Acta pharmaceutica Sinica. B, 14(9), 3818-3833. https://doi.org/10.1016/j.apsb.2024.05.013